ArticleJournal of pharmaceutical analysis2026
Integrating mass spectrometry imaging and data-driven segmentation for spatial metabolic mapping of diabetic eye disease.
Article in Journal of pharmaceutical analysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic eye disease (DED) is a leading cause of vision impairment worldwide, yet the molecular mechanisms underlying its progression remain incompletely understood. In this study, we applied a dual-platform spatial metabolomics strategy integrating air flow-assisted desorption electrospray ionization mass spectrometry imaging (AFADESI-MSI) and matrix-assisted laser desorption ionization mass spectrometry imaging (MALDI-MSI) to characterize spatial metabolic alterations in the eyes of diabetic rats. Data-driven segmentation of retinal micro-regions using SCiLS Lab software enabled fine-scale mapping of metabolic heterogeneity. Physiological, biochemical, and histopathological analyses were combined with spatial metabolite mapping to construct a metabolic atlas and evaluate the regulatory effects of ferulic acid. We established a comprehensive spatial metabolome atlas of the rat eye, identifying 135 annotated metabolites and revealing significant region-specific metabolic heterogeneity. Unsupervised k-means clustering was further applied to the high-resolution MALDI-MSI data, successfully delineating distinct functional micro-regions of the retina solely based on endogenous metabolic profiles, demonstrating the power of data-driven tissue segmentation. In diabetic eyes, 39 metabolites were significantly dysregulated, involving amino acid, glucose, lipid, and redox metabolism. Notably, lysine, arginine, carnitine, and glutathione (GSH) were depleted, while glucose-6-phosphate (G6P), glycerol-3-phosphate (G3P), and pro-inflammatory lipids were elevated, highlighting profound metabolic reprogramming across ocular compartments. Ferulic acid treatment restored nine key metabolites, alleviated oxidative stress, normalized lipid and glucose metabolism, and improved retinal structural integrity in a dose-dependent manner. This study shows that integrating mass spectrometry imaging with data-driven tissue segmentation reveals spatial metabolic reprogramming in DED and highlights ferulic acid as a promising therapeutic candidate.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.